IPHYF - Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript
2024-05-14 11:03:08 ET
Innate Pharma S.A. (IPHA)
Q1 2024 Results Conference Call
May 14, 2024 08:00 AM ET
Company Participants
Henry Wheeler - Head, Investor Relations
Herve Brailly - Interim Chief Executive Officer
Sonia Quaratino - Chief Medical Officer
Yannis Morel - Chief Operating Officer
Arvind Sood - EVP, U.S. Operations
Frederic Lombard - Chief Financial Officer
Conference Call Participants
Daina Graybosch - Leerink Partners
Yigal Nochomovitz - Citigroup
Swayampakula Ramakanth - HCW
Rajan Sharma - Goldman Sachs
Jingming Chen - Evercore ISI
Presentation
Operator
Thank you for standing by, and welcome to the Innate Pharma First Quarter 2024 Financial Results and Business Update Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions]
I'd now like to turn the call over to Henry Wheeler, Vice President, Investor Relations and Communications. You may begin.
Henry Wheeler
Thank you. Good morning, good afternoon, and welcome everyone.
This morning Innate issued a press release for our Q1 2024 business update and financial results. We look forward to highlighting the progress made during the year-to-date, during the quarter-to-date, as well as addressing future goals and milestones. The press release in today's presentation are both available on the IR section of the website.
On Slide 2, before we start, I'd like to remind you that we'll be making forward-looking statements regarding our financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted....
Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript